Alan H. Bryce, MD, presented “Management of mHSPC-Singlets and Doublets and Triplets” during the 26th Annual Southwest Prostate Cancer Symposium conference on April 15, 2023, in Scottsdale, Arizona.
How to cite: Bryce, Alan H. “Management of mHSPC-Singlets and Doublets and Triplets.” April 15, 2023. Accessed Dec 2025. https://grandroundsinurology.com/management-of-mhspc-singlets-and-doublets-and-triplets/
Management of mHSPC-Singlets and Doublets and Triplets – Summary
Alan H. Bryce, MD, discusses metastatic hormone-sensitive prostate cancer (mHSPC) and the importance of early and effective treatment to improve patient outcomes. While singlet therapy, which typically involves androgen deprivation therapy (ADT) alone, has been the traditional approach, newer evidence supports the use of combination therapies.
Data on doublet therapy, combining ADT with either chemotherapy or a novel hormonal agent such as abiraterone, enzalutamide, or apalutamide, have demonstrated significant improvements in overall survival and progression-free survival compared to ADT alone. Key studies, including the LATITUDE and CHAARTED trials, have established the efficacy of these doublet regimens.
Dr. Bryce also explores adding a second novel agent or chemotherapy to the ADT and initial novel agent combination (triplet therapy). He notes that while triplet therapy may offer further survival advantages, it also carries an increased risk of side effects and requires careful patient selection and management.
About the 26th Annual Southwest Prostate Cancer Symposium:
This conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
Alan H. Bryce, MD, is a Medical Oncologist and Chief Clinical Officer at City of Hope in Phoenix, Arizona. Dr. Bryce holds an appointment as a Professor with the Department of Medical Oncology & Therapeutics Research and as a Professor of Molecular Medicine at Translational Genomics Research Institute (TGen), both a part of City of Hope.
